- Home
- RLTY vs CLLS Comparison
RLTY vs CLLS Comparison
Compare RLTY & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- CLLS
- Stock Information
- Founded
- RLTY 2022
- CLLS 1999
- Country
- RLTY United States
- CLLS France
- Employees
- RLTY N/A
- CLLS N/A
- Industry
- RLTY Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- CLLS Health Care
- Exchange
- RLTY Nasdaq
- CLLS Nasdaq
- Market Cap
- RLTY 250.8M
- CLLS 299.0M
- IPO Year
- RLTY N/A
- CLLS 2007
- Fundamental
- Price
- RLTY $14.96
- CLLS $3.85
- Analyst Decision
- RLTY
- CLLS Buy
- Analyst Count
- RLTY 0
- CLLS 1
- Target Price
- RLTY N/A
- CLLS $8.00
- AVG Volume (30 Days)
- RLTY 86.7K
- CLLS 76.7K
- Earning Date
- RLTY 01-01-0001
- CLLS 11-07-2025
- Dividend Yield
- RLTY 9.35%
- CLLS N/A
- EPS Growth
- RLTY N/A
- CLLS N/A
- EPS
- RLTY N/A
- CLLS N/A
- Revenue
- RLTY N/A
- CLLS $82,551,000.00
- Revenue This Year
- RLTY N/A
- CLLS N/A
- Revenue Next Year
- RLTY N/A
- CLLS $58.00
- P/E Ratio
- RLTY N/A
- CLLS N/A
- Revenue Growth
- RLTY N/A
- CLLS 129.04
- 52 Week Low
- RLTY $11.38
- CLLS $1.10
- 52 Week High
- RLTY $14.60
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- RLTY 45.81
- CLLS 58.54
- Support Level
- RLTY $14.94
- CLLS $3.49
- Resistance Level
- RLTY $15.39
- CLLS $3.86
- Average True Range (ATR)
- RLTY 0.19
- CLLS 0.22
- MACD
- RLTY 0.01
- CLLS 0.03
- Stochastic Oscillator
- RLTY 37.10
- CLLS 89.76
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.